On August 2, with the approval of the Food and Drug Department (FDD) of the Lao Ministry of Health, Larotrectinib, produced by TLPH , was officially approved for marketing. The approved Larotrectinib, trade name Larotreni, capsules, is divided into two specifications, 100mg/capsule*60 capsules/bottle, 25mg/capsule*60 capsules/bottle.

      Larotrectinib was approved by the U.S. Food and Drug Administration on November 26, 2018, for the treatment of adult and pediatric patients with solid tumors with NTRK gene fusions. Larotrectinib is the world's first broad-spectrum anticancer drug approved by the FDA regardless of tumor type!

      At this point, TLPH has two broad-spectrum anticancer drugs, including Larotrectinib and Entrectinib, which fully demonstrates  TLPH’s technical strength and patient-centered enterprise philosophy, and continues to consolidate its leading position as a pharmaceutical endorsement company in Laos!